RECOMBINATE 500 IU

Pays: Israël

Langue: anglais

Source: Ministry of Health

Ingrédients actifs:

COAGULATION FACTOR VIII RECOMBINANT 500 IU/VIAL

Disponible depuis:

TEVA MEDICAL MARKETING LTD.

Code ATC:

B02BD05

forme pharmaceutique:

POWDER FOR SOLUTION FOR INJECTION

Mode d'administration:

I.V

Fabriqué par:

BAXTER S.A., BELGIUM

Groupe thérapeutique:

COAGULATION FACTOR VII

indications thérapeutiques:

The use of Recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Recombinate is also indicated in the perioperative management of patients with haemophilia A. Recombinate is appropriate for use in children of all ages including the newborn. (Safety and efficacy studies have been performed in both previously treated and previously untreated children). The product in not suitable for the treatment of von Willebrand's disease.

Date de l'autorisation:

2010-07-01